![[Düzenle]](?edit=/home/u514654129/domains/awesamohealth.com/public_html/wp-content/themes/pixwell/screenshot.png){kind=link}
![[Yeniden Adlandır]](?rename=/home/u514654129/domains/awesamohealth.com/public_html/wp-content/themes/pixwell/screenshot.png){kind=link}
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Kroemer, G., McQuade, J. L., Merad, M., André, F. & Zitvogel, L. Bodywide ecological interventions on cancer. Nat. Med. 29, 59–74 (2023).
Sharma, P. et al. Immune checkpoint therapy—current perspectives and future directions. Cell 186, 1652–1669 (2023).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212–224 (2021).
Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825–1863 (2024). This review proposes a novel ‘three Cs’ framework for the molecular mechanisms by which malignant cells evade immunosurveillance: camouflage, coercion and cytoprotection.
Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. Nat. Rev. Immunol. 20, 75–76 (2020).
Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer 24, 498–512 (2024).
Anagnostou, V., Bardelli, A., Chan, T. A. & Turajlic, S. The status of tumor mutational burden and immunotherapy. Nat. Cancer 3, 652–656 (2022).
Yamaguchi, H., Hsu, J. M., Yang, W. H. & Hung, M. C. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat. Rev. Clin. Oncol. 19, 287–305 (2022).
Kroemer, G., Senovilla, L., Galluzzi, L., André, F. & Zitvogel, L. Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 21, 1128–1138 (2015).
Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554–577 (2024).
Schmid, P. et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N. Engl. J. Med. 391, 1981–1991 (2024).
Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217–226 (2022).
Giaquinto, A. N. et al. Breast cancer statistics 2024. CA Cancer J. Clin. 74, 477–495 (2024).
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479 (2016).
Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330–1345.e18 (2019). This study uses mass cytometry for the detection of 73 proteins in 26 million cells from 144 human breast cancers and 50 healthy mammary tissue samples to provide an in-depth molecular characterization of human breast cancer heterogeneity across patients and disease stages.
Barroso-Sousa, R. et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann. Oncol. 31, 387–394 (2020).
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
Thomas, A. et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology 7, e1490854 (2018).
Tarantino, P. et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat. Commun. 14, 7496 (2023).
Van Baelen, K. et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann. Oncol. 33, 769–785 (2022).
Goh, G. et al. Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: a phase II open-label clinical trial of afatinib +/– vinorelbine. PLoS Med. 13, e1002136 (2016).
Bertucci, F. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560–564 (2019).
Garrido-Castro, A. C. et al. Genomic characterization of de novo metastatic breast cancer. Clin. Cancer Res. 27, 1105–1118 (2021).
Safonov, A. et al. Immune gene expression is associated with genomic aberrations in breast cancer. Cancer Res. 77, 3317–3324 (2017).
Aftimos, P. et al. Genomic and Transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 11, 2796–2811 (2021).
Kanu, N. et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 17, 185 (2016).
Wu, R. et al. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival. Am. J. Cancer Res. 12, 744–762 (2022).
Asaoka, M., Patnaik, S. K., Ishikawa, T. & Takabe, K. Different members of the APOBEC3 family of DNA mutators have opposing associations with the landscape of breast cancer. Am. J. Cancer Res. 11, 5111–5125 (2021).
Pecori, R., Di Giorgio, S., Paulo Lorenzo, J. & Nina Papavasiliou, F. Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination. Nat. Rev. Genet. 23, 505–518 (2022).
Venkatesan, S. et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 11, 2456–2473 (2021).
Caswell, D. R. et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nat. Genet. 56, 60–73 (2024).
Winter, C. et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann. Oncol. 27, 1532–1538 (2016).
Kraya, A. A. et al. Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer. Clin. Cancer Res. 25, 4363–4374 (2019).
Zhao, W., Wiese, C., Kwon, Y., Hromas, R. & Sung, P. The BRCA tumor suppressor network in chromosome damage repair by homologous recombination. Annu. Rev. Biochem. 88, 221–245 (2019).
Schwartz, C. J. et al. Morphologic and genomic characteristics of breast cancers occurring in individuals with Lynch syndrome. Clin. Cancer Res. 28, 404–413 (2022).
Klapp, V. et al. The DNA damage response and inflammation in cancer. Cancer Discov. 13, 1521–1545 (2023).
Hendrickx, W. et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology 6, e1253654 (2017).
Zhu, Y. et al. Characterization of neoantigen load subgroups in gynecologic and breast cancers. Front. Bioeng. Biotechnol. 8, 702 (2020).
De Mattos-Arruda, L. et al. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. NPJ Breast Cancer 7, 73 (2021).
Karn, T. et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 3, 1707–1711 (2017).
McGrail, D. J. et al. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat. Commun. 9, 1317 (2018).
Winer, E. P. et al. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. J. Clin. Oncol. 38, 1013–1013 (2020).
Barroso-Sousa, R. et al. Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit. JCO Precis. Oncol. 6, e2100413 (2022).
Vega, D. M. et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann. Oncol. 32, 1626–1636 (2021).
Yoo, S. K. et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat. Med. 31, 869–880 (2025).
Yang, K., Halima, A. & Chan, T. A. Antigen presentation in cancer—mechanisms and clinical implications for immunotherapy. Nat. Rev. Clin. Oncol. 20, 604–623 (2023).
Filip, I. et al. Pervasiveness of HLA allele-specific expression loss across tumor types. Genome Med. 15, 8 (2023).
Tsang, J. Y. et al. Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers. Cancer Immunol. Immunother. 69, 799–811 (2020).
Lee, H. J. et al. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget 7, 30119–30132 (2016).
Garcia-Recio, S. et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat. Cancer 4, 128–147 (2023).
Szekely, B. et al. Immunological differences between primary and metastatic breast cancer. Ann. Oncol. 29, 2232–2239 (2018).
Sinn, B. V. et al. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res. 21, 142 (2019).
Muntasell, A. et al. NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival. Clin. Cancer Res. 25, 1535–1545 (2019).
Noblejas-Lopez, M. D. M. et al. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. Oncoimmunology 8, e1629780 (2019).
de Groot, A. F. et al. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 175, 605–615 (2019).
Sinn, B. V. et al. Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer. Clin. Cancer Res. 27, 2584–2591 (2021).
Luo, N. et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat. Commun. 9, 248 (2018).
Henle, A. M., Nassar, A., Puglisi-Knutson, D., Youssef, B. & Knutson, K. L. Downregulation of TAP1 and TAP2 in early stage breast cancer. PLoS ONE 12, e0187323 (2017).
Pedersen, M. H. et al. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. Oncoimmunology 6, e1305531 (2017).
Liu, Y. et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol. Immunother. 61, 789–801 (2012).
Kaklamanis, L., Leek, R., Koukourakis, M., Gatter, K. C. & Harris, A. L. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55, 5191–5194 (1995).
Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020).
Loi, S. et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann. Oncol. 32, 1236–1244 (2021).
Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40–50 (2018).
Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat. Cancer 1, 163–175 (2020).
Solinas, C. et al. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Lett. 450, 88–97 (2019).
Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J. Natl Cancer Inst. 109, djw199 (2017).
Arnedos, M. et al. Genomic and immune characterization of metastatic breast cancer (mBC): and ancillary study of the Safir01 & Moscato trials. Ann. Oncol. 25, iv116 (2014).
Zeppellini, A. et al. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2– breast cancers: results of a pilot study. BMC Cancer 21, 260 (2021).
Mutka, M., Joensuu, K., Eray, M. & Heikkilä, P. Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar. Diagn. Pathol. 18, 3 (2023).
Cimino-Mathews, A., Ye, X., Meeker, A., Argani, P. & Emens, L. A. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum. Pathol. 44, 2055–2063 (2013).
Zhu, L. et al. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. J. Immunother. Cancer 7, 265 (2019).
Plitas, G. et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45, 1122–1134 (2016).
Jiang, D., Gao, Z., Cai, Z., Wang, M. & He, J. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer 15, 727 (2015).
Bates, G. J. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373–5380 (2006).
Li, F., Zhao, Y., Wei, L., Li, S. & Liu, J. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol. Ther. 19, 695–705 (2018).
Lee, Y. J. et al. CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. Sci. Immunol. 7, eabn8390 (2022).
Virassamy, B. et al. Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell 41, 585–601.e8 (2023).
Hayashi, K. et al. Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer. Front. Oncol. 12, 901591 (2022).
Núñez, N. G. et al. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat. Commun. 11, 3272 (2020).
Oner, G. et al. The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy. Cancer Med. 12, 17901–17913 (2023).
Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105–113 (2010). This work pioneers the discovery that an abundant lymphocytic compartment predicts responsiveness to neoadjuvant chemotherapy in patients with TNBC, independently of standard clinico-pathological factors.
Pelekanou, V. et al. Tumor-infiltrating lymphocytes and PD-L1 expression in pre- and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial. Mol. Cancer Ther. 17, 1324–1331 (2018).
Fernandez-Martinez, A. et al. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol. 9, 490–499 (2023).
Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559–569 (2019).
Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544–1550 (2014).
Krishnamurti, U., Wetherilt, C. S., Yang, J., Peng, L. & Li, X. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum. Pathol. 64, 7–12 (2017).
Lee, H. J. et al. Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab. Am. J. Clin. Pathol. 144, 278–288 (2015).
Massa, D. et al. Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer. J. Natl Cancer Inst. 116, 1914–1927 (2024).
Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259–271 (2015).
Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25, 1536–1543 (2014).
Griguolo, G. et al. A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. Neuro Oncol. 24, 2146–2158 (2022).
Luo, L. et al. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2– metastatic breast cancer. Mol. Cancer 24, 48 (2025).
Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920–928 (2019). This article suggests that induction chemotherapy with cisplatin or doxorubicin is superior to other strategies to improve the sensitivity of patients with metastatic TNBC to subsequent PD1 blockade.
Gu-Trantien, C. et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013).
Pellegrino, B. et al. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016). J. Immunother. Cancer 11, e007667 (2023).
Iglesia, M. D. et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin. Cancer Res. 20, 3818–3829 (2014).
Garaud, S. et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight 5, e129641 (2019).
Mamessier, E. et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121, 3609–3622 (2011).
Thacker, G. et al. Immature natural killer cells promote progression of triple-negative breast cancer. Sci. Transl. Med. 15, eabl4414 (2023).
Rethacker, L. et al. Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes. Oncoimmunology 11, 2057396 (2022).
Waks, A. G. et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clin. Cancer Res. 25, 4644–4655 (2019).
Gazinska, P. et al. Dynamic changes in the NK-, neutrophil-, and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant chemotherapy-resistant early breast cancers. Clin. Cancer Res. 28, 4494–4508 (2022).
Petroni, G. et al. IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2– breast cancer via CX3CR1+ macrophages. Nat. Cancer 6, 1656–1675 (2025). This article shows that HR+HER2– breast tumours exposed to CDK4/6 inhibitors recruit γδ T cells, resulting in the IL-17-dependent repolarization of local macrophages towards an immunosuppressive phenotype associated with therapy resistance.
Kuroda, H. et al. Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer. Breast Cancer 28, 904–914 (2021).
Kuroda, H. et al. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. BMC Cancer 21, 286 (2021).
Rediti, M. et al. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nat. Commun. 14, 7053 (2023).
Angelats, L. et al. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. ESMO Open. 10, 104109 (2025).
Wang, Q. et al. Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer. Br. J. Cancer 132, 295–310 (2025).
Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178–191 (2023).
Boissiere-Michot, F. et al. Clinicopathological Correlates of γδ T cell infiltration in triple-negative breast cancer. Cancers 13, 765 (2021).
Wu, Y. et al. An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Sci. Transl. Med. 11, eaax9364 (2019).
Craven, K. E., Gökmen-Polar, Y. & Badve, S. S. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci. Rep. 11, 4691 (2021).
Bense, R. D. et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J. Natl Cancer Inst. 109, djw192 (2017).
Mahmoud, S. M. et al. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J. Clin. Pathol. 65, 159–163 (2012).
Valeta-Magara, A. et al. Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network. Cancer Res. 79, 3360–3371 (2019).
Mehta, A. K. et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat. Cancer 2, 66–82 (2021). This article provides an elegant demonstration that immunosuppressive TAMs limit the sensitivity of breast cancers bearing BRCA1 mutations to PARP inhibitors, identifying CSF1R as a potential target to circumvent this resistance mechanism.
Tharp, K. M. et al. Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nat. Cancer 5, 1045–1062 (2024).
O’Meara, T. et al. Immunological differences between immune-rich estrogen receptor-positive and immune-rich triple-negative breast cancers. JCO Precis. Oncol. 4, PO.19.00350 (2020).
Yofe, I. et al. Spatial and temporal mapping of breast cancer lung metastases identify TREM2 macrophages as regulators of the metastatic boundary. Cancer Discov. 13, 2610–2631 (2023).
Cha, S. M. et al. SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes. NPJ Breast Cancer 10, 83 (2024).
Nalio Ramos, R. et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell 185, 1189–1207.e25 (2022). This work shows that FOLR2+ TAMs localizing to perivascular areas of the TME prime potent antitumour immune responses in mouse models of breast cancer and are associated with improved disease outcome in patients.
Tkach, M. et al. Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome. Proc. Natl Acad. Sci. USA 119, e2107394119 (2022).
Chen, Y., Klingen, T. A., Aas, H., Wik, E. & Akslen, L. A. CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis. J. Pathol. Clin. Res. 9, 151–164 (2023).
Honkanen, T. J. et al. Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. Sci. Rep. 9, 10961 (2019).
Ramos, R. N. et al. CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clin. Transl. Immunol. 9, e1108 (2020).
Janiszewska, M. et al. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. JCI Insight 6, e147617 (2021).
Lespagnard, L. et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int. J. Cancer 84, 309–314 (1999).
Bell, D. et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190, 1417–1426 (1999).
Sisirak, V. et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 72, 5188–5197 (2012).
De Martino, M., Rathmell, J. C., Galluzzi, L. & Vanpouille-Box, C. Cancer cell metabolism and antitumour immunity. Nat. Rev. Immunol. 24, 654–669 (2024).
Tietscher, S. et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat. Commun. 14, 98 (2023).
Wu, S. Y. et al. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med 4, 373–393.e8 (2023).
Li, S. et al. Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients. Mol. Cancer 23, 216 (2024).
Dent, R. et al. Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. Breast Cancer Res. 27, 35 (2025).
Treilleux, I. et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10, 7466–7474 (2004).
Ruiz-Iglesias, A., Guilbaud, E., Galluzzi, L. & Manes, S. Context-dependent impact of type I interferon signaling in cancer. Mol. Cancer 24, 275 (2025).
Jiménez-Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I. & Galluzzi, L. Myeloid-derived suppressor cells and radiotherapy. Cancer Immunol. Res. 10, 545–557 (2022).
Wu, L. et al. Breast cancer cell–neutrophil interactions enhance neutrophil survival and pro-tumorigenic activities. Cancers 12, 2884 (2020).
Yu, J. et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190, 3783–3797 (2013).
Coffelt, S. B. et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345–348 (2015).
Tabariès, S. et al. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res. 17, 45 (2015).
Rozalen, C. et al. TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak. Cancer Cell 43, 1549–1567.e9 (2025).
Gong, Z. et al. Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis. Sci. Immunol. 8, eadd5204 (2023).
Ma, T. et al. Chronic pulmonary bacterial infection facilitates breast cancer lung metastasis by recruiting tumor-promoting MHCIIhi neutrophils. Signal. Transduct. Target. Ther. 8, 296 (2023).
Li, W. et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 28, 87–103.e6 (2018).
Danenberg, E. et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat. Genet. 54, 660–669 (2022).
Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).
Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2, 361–370 (2014).
Emens, L. A. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J. Natl Cancer Inst. 113, 1005–1016 (2021).
Wimberly, H. et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol. Res. 3, 326–332 (2015).
Hsu, J. M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018).
Galassi, C., Esteller, M., Vitale, I. & Galluzzi, L. Epigenetic control of immunoevasion in cancer stem cells. Trends Cancer 10, 1052–1071 (2024).
Carter, J. M. et al. Characteristics and spatially defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer. Clin. Cancer Res. 27, 5628–5637 (2021).
Li, M. et al. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer 18, 4 (2018).
Boman, C. et al. Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis. Cancer Treat. Rev. 99, 102257 (2021).
Tawfik, O., Kimler, B. F., Karnik, T. & Shehata, P. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells. Hum. Pathol. 80, 170–178 (2018).
Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 5, 74–82 (2019).
Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44–59 (2020).
Ignatiadis, M. et al. Adjuvant atezolizumab for early triple-negative breast cancer: the ALEXANDRA/IMpassion030 randomized clinical trial. JAMA 333, 1150–1160 (2025).
Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817–1828 (2020).
Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810–821 (2020).
Badve, S. S. et al. Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130. J. Natl Cancer Inst. 114, 664–675 (2022).
Yuan, J. et al. High expression of CD47 in triple negative breast cancer is associated with epithelial–mesenchymal transition and poor prognosis. Oncol. Lett. 18, 3249–3255 (2019).
Candas-Green, D. et al. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat. Commun. 11, 4591 (2020).
Kristiansen, G. et al. CD24 expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 9, 4906–4913 (2003).
Surowiak, P. et al. Multivariate analysis of oestrogen receptor α, pS2, metallothionein and CD24 expression in invasive breast cancers. Br. J. Cancer 95, 339–346 (2006).
Mylona, E. et al. The clinicopathologic and prognostic significance of CD44+/CD24–/low and CD44–/CD24+ tumor cells in invasive breast carcinomas. Hum. Pathol. 39, 1096–1102 (2008).
Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019). These authors show that CD24 is a major checkpoint against phagocytosis in ovarian cancer and breast cancer, pointing to CD24-blocking interventions as promising combinatorial targets for ICIs in these oncological indications.
Weichselbaum, R. R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl Acad. Sci. USA 105, 18490–18495 (2008).
Rodriguez-Ruiz, M. E. et al. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology 8, e1655964 (2019).
Holicek, P. et al. Type I interferon and cancer. Immunol. Rev. 321, 115–127 (2024).
Hou, J., Karin, M. & Sun, B. Targeting cancer-promoting inflammation—have anti-inflammatory therapies come of age? Nat. Rev. Clin. Oncol. 18, 261–279 (2021).
Musella, M. et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat. Immunol. 23, 1379–1392 (2022).
Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620, 1080–1088 (2023). This study shows that chromosomal instability fosters breast cancer progression and metastatic dissemination downstream of cGAS–STING signalling and consequent secretion of immunosuppressive cytokines.
Richardson, L., Wilcockson, S. G., Guglielmi, L. & Hill, C. S. Context-dependent TGFβ family signalling in cell fate regulation. Nat. Rev. Mol. Cell Biol. 24, 876–894 (2023).
Auvinen, P., Lipponen, P., Johansson, R. & Syrjanen, K. Prognostic significance of TGF-β1 and TGF-β2 expressions in female breast cancer. Anticancer. Res. 15, 2627–2631 (1995).
Gomis, R. R., Alarcón, C., Nadal, C., Van Poznak, C. & Massagué, J. C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10, 203–214 (2006).
Dong, M. et al. The type III TGF-β receptor suppresses breast cancer progression. J. Clin. Invest. 117, 206–217 (2007).
Koumoundourou, D. et al. Prognostic significance of TGFβ-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours. Anticancer. Res. 27, 2613–2620 (2007).
Bierie, B. et al. Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119, 1571–1582 (2009).
Hachim, I. Y., Hachim, M. Y., López-Ozuna, V. M., Ali, S. & Lebrun, J. J. A dual prognostic role for the TGFβ receptors in human breast cancer. Hum. Pathol. 57, 140–151 (2016).
de Kruijf, E. M. et al. The prognostic role of TGF-β signaling pathway in breast cancer patients. Ann. Oncol. 24, 384–390 (2013).
Bhola, N. E. et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348–1358 (2013).
Yang, Y. et al. The outcome of TGFβ antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and proprogression activities of TGFβ. Clin. Cancer Res. 26, 643–656 (2020).
Czabotar, P. E. & Garcia-Saez, A. J. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nat. Rev. Mol. Cell Biol. 24, 732–748 (2023).
Merino, D., Lok, S. W., Visvader, J. E. & Lindeman, G. J. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene 35, 1877–1887 (2016).
McArthur, K. et al. BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science 359, eaao6047 (2018).
Yamazaki, T. et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat. Immunol. 21, 1160–1171 (2020). Together with McArthur et al. (2018), this work shows that mitochondrial DNA can be released into the cytosol of stressed (cancer) cells in a BCL2-inhibitable manner.
Zhao, L. et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 13, 2448–2469 (2023).
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725–741 (2020).
Petroni, G., Buqué, A., Coussens, L. M. & Galluzzi, L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat. Rev. Drug. Discov. 21, 440–462 (2022).
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C. & Galluzzi, L. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nat. Rev. Clin. Oncol. 19, 114–131 (2022).
Gibney, G. T. et al. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J. Immunother. Cancer 7, 80 (2019).
Mitchell, T. C. et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J. Clin. Oncol. 36, 3223–3230 (2018).
Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 20, 1083–1097 (2019).
Mariotti, V. et al. Effect of taxane chemotherapy with or without indoximod in metastatic breast cancer: a randomized clinical trial. JAMA Oncol. 7, 61–69 (2021).
Formenti, S. C. et al. Focal irradiation and systemic TGFβ blockade in metastatic breast cancer. Clin. Cancer Res. 24, 2493–2504 (2018).
Demaria, S., Romano, E., Brackstone, M. & Formenti, S. C. Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial. J. Immunother. Cancer 7, 318 (2019).
Rugo, H. S. et al. Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: phase 1b study. NPJ Breast Cancer 8, 118 (2022).
Emens, L. A. et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 21, 1283–1295 (2020).
Huober, J. et al. Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial. J. Clin. Oncol. 40, 2946–2956 (2022).
Loibl, S. et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N. Engl. J. Med. 394, 845–857 (2026).
Schmid, P. et al. Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study. Cancer Res. 83, PD11-08 (2023).
Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433–441 (2025).
Chung, H. C. et al. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 study. Cancer 130, 3278–3288 (2024).
Chen, L. et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial. Clin. Cancer Res. 28, 2807–2817 (2022).
Zacharakis, N. et al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J. Clin. Oncol. 40, 1741–1754 (2022).
Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171–1182 (2025). These authors report on the safety and feasibility of using CAR-expressing macrophages directed against HER2 in patients with advanced HER2-overexpressing breast cancer.
Tchou, J. et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol. Res. 5, 1152–1161 (2017).
Shah, P. D. et al. Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res. Commun. 3, 821–829 (2023).
Domchek, S. M. et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 21, 1155–1164 (2020).
Pusztai, L. et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell 39, 989–998.e5 (2021).
Han, H. S. et al. Alteration of the tumor microenvironment with intratumoral dendritic cells before chemotherapy in ERBB2 breast cancer: a nonrandomized clinical trial. JAMA Oncol. 11, 119–127 (2025).
Soliman, H. et al. A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER– breast cancer. NPJ Breast Cancer 11, 29 (2025).
Zhang, X. et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 16, 131 (2024).
Disis, M. L. N. et al. Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 Nonrandomized clinical trial. JAMA Oncol. 9, 71–78 (2023).
Hernandez-Aya, L. F. et al. A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol. 37, TPS1114 (2019).
Hatem, S. et al. Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC). Cancer Res. 82, P5-16-02 (2022).
Autio, K. A. et al. Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study. Clin. Cancer Res. 26, 5609–5620 (2020).
Roussos Torres, E. T. et al. Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nat. Cancer 5, 866–879 (2024).
Hu, X. et al. Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort. Nat. Commun. 16, 4324 (2025).
Palmer, C. L. et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell 43, 464–481.e14 (2025).
Frentzas, S. et al. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. J. Immunother. Cancer 12, e008037 (2024).
Fusco, N. & Viale, G. The “lows”: update on ER-low and HER2-low breast cancer. Breast 78, 103831 (2024).
Virassamy, B. et al. Parity and lactation induce T-cell-mediated breast cancer protection. Nature 649, 449–459 (2026).
Brown, K. A. Metabolic pathways in obesity-related breast cancer. Nat. Rev. Endocrinol. 17, 350–363 (2021).
Prat, A. & Baselga, J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat. Clin. Pract. Oncol. 5, 531–542 (2008).
Nielsen, T. O. et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 5222–5232 (2010).
Hamilton, E., Shastry, M., Shiller, S. M. & Ren, R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat. Rev. 100, 102286 (2021).
Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers 5, 66 (2019).
Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345–359 (2021).
Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst. 106, dju124 (2014).
Ray-Coquard, I. et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 69, 5383–5391 (2009).
Cupp, M. A. et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 18, 360 (2020).
Garcia-Torralba, E. et al. Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes. Breast Cancer Res. Treat. 205, 475–485 (2024).
Ethier, J. L., Desautels, D., Templeton, A., Shah, P. S. & Amir, E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 19, 2 (2017).
Ivars Rubio, A. et al. Neutrophil–lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables. Sci. Rep. 9, 16979 (2019).
Kim, J. Y. et al. Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC Cancer 20, 1206 (2020).
Cho, K. M. et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. Oncotarget 8, 2329–2341 (2017).
Savioli, F. et al. Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis. Br. J. Surg. 109, 1206–1215 (2022).
Wang, L. et al. IL6 signaling in peripheral blood t cells predicts clinical outcome in breast cancer. Cancer Res. 77, 1119–1126 (2017).
Wang, L. et al. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat. Immunol. 20, 1220–1230 (2019).
Varchetta, S. et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67, 11991–11999 (2007).
Axelrod, M. L. et al. Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer. Clin. Cancer Res. 26, 5668–5681 (2020).
Muntasell, A. et al. High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer. Cancer Immunol. Res. 7, 1280–1292 (2019).
Santana-Hernández, S. et al. NK cell-triggered CCL5/IFNγ–CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J. Exp. Clin. Cancer Res. 43, 10 (2024).
Divella, R. et al. Circulating levels of transforming growth factor-β (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer. Res. 33, 1491–1497 (2013).
Kettner, N. M. et al. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR+/HER2-negative metastatic breast cancer. NPJ Precis. Oncol. 9, 260 (2025).
Benoy, I. H. et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10, 7157–7162 (2004).
Teillaud, J. L., Houel, A., Panouillot, M., Riffard, C. & Dieu-Nosjean, M. C. Tertiary lymphoid structures in anticancer immunity. Nat. Rev. Cancer 24, 629–646 (2024).
Figenschau, S. L., Fismen, S., Fenton, K. A., Fenton, C. & Mortensen, E. S. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer 15, 101 (2015).
Lee, H. J. et al. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J. Clin. Pathol. 69, 422–430 (2016).
Lee, M. et al. Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Mod. Pathol. 32, 70–80 (2019).
Kasikova, L. et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat. Commun. 15, 2528 (2024).
Keren, L. et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 174, 1373–1387.e19 (2018).
Galluzzi, L., Smith, K. N., Liston, A. & Garg, A. D. The diversity of CD8+ T cell dysfunction in cancer and viral infection. Nat. Rev. Immunol. 25, 662–679 (2025).
Wortman, J. C. et al. Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. NPJ Breast Cancer 7, 84 (2021).
Shiao, S. L. et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell 42, 70–84.e8 (2024). This work defines the immunological changes elicited by neoadjuvant PD1 blockade followed by PD1 blockade and hypofractionated radiotherapy in patients with TNBC, highlighting two different trajectories associated with pCR at surgery.
Hammerl, D. et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat. Commun. 12, 5668 (2021).
Gruosso, T. et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J. Clin. Invest. 129, 1785–1800 (2019).
Palomeque, J. A. et al. Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer. J. Clin. Invest. 136, e193153 (2026).
Shimada, K. et al. An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer. Preprint at bioRxiv https://doi.org/10.1101/2024.11.23.619172 (2024).
Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2– breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442–448 (2025).
Tinoco, J. C. et al. Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer. J. Immunother. Cancer 13, e010179 (2025).
Yu, J. et al. Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. Cell 187, 4713–4732.e19 (2024).
Werner, L. R. et al. Progesterone promotes immunomodulation and tumor development in the murine mammary gland. J. Immunother. Cancer 9, e001710 (2021).
Hu, D. et al. p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy. Nat. Cancer 6, 1202–1222 (2025).
Li, Y. et al. Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer Cell 42, 985–1002.e18 (2024).
Modi, S. et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat. Med. 31, 4205–4213 (2025).
Onkar, S. S. et al. The great immune escape: understanding the divergent immune response in breast cancer subtypes. Cancer Discov. 13, 23–40 (2023).
Denkert, C. et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer—from intrinsic to adaptive subtyping. Cancer Cell 43, 232–247.e4 (2025).
Correia, A. L. Locally sourced: site-specific immune barriers to metastasis. Nat. Rev. Immunol. 23, 522–538 (2023).
Fu, A. et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185, 1356–1372.e26 (2022). These authors use a genetically modified preclinical model of HER2+ breast cancer to show that the tumour-resident bacterial microbiome promotes metastatic dissemination to the lung without affecting primary tumour growth.
Chen, J. et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell 43, 361–379.e10 (2025).
Sceneay, J. et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative. Breast Cancer. Cancer Discov. 9, 1208–1227 (2019).
Dumas, E. et al. Concomitant medication, comorbidity and survival in patients with breast cancer. Nat. Commun. 15, 2966 (2024).
Buqué, A. et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat. Commun. 11, 3819 (2020).
Kos, Z. et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 6, 17 (2020).
Martin, M. et al. Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy. Clin. Cancer Res. 30, 2160–2169 (2024).
Nederlof, I. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat. Med. 30, 3223–3235 (2024).
Kok, M. et al. Academic uphill battle to personalize treatment for patients with stage II/III triple-negative breast cancer. J. Clin. Oncol. 42, 3523–3529 (2024).
Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
Buqué, A. & Galluzzi, L. Modeling tumor immunology and immunotherapy in mice. Trends Cancer 4, 599–601 (2018).
Solomon, D. A. et al. Sample type bias in the analysis of cancer genomes. Cancer Res. 69, 5630–5633 (2009).
Sedrak, M. S. et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J. Clin. 71, 78–92 (2021).
Ye, Y. et al. Sex-associated molecular differences for cancer immunotherapy. Nat. Commun. 11, 1779 (2020).
Petroni, G. & Galluzzi, L. Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents. Oncoimmunology 10, 1889101 (2021).
Villacampa, G. et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA Oncol. 10, 1331–1341 (2024).
Ríos-Hoyo, A. et al. Neoadjuvant chemotherapy and immunotherapy for estrogen receptor–positive human epidermal growth factor 2-negative breast cancer. J. Clin. Oncol. 42, 2632–2636 (2024).
Miles, D. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann. Oncol. 32, 994–1004 (2021).